Aromatase Inhibitors and Evolution of the Lipid Profile (Clinical Report‪)‬

Introduction Breast cancer therapy trials often report serum lipid parameters, but assessing the quality and overall significance of the data can be difficult. Methodology of data collection varies among trials, and the concomitant use of lipid-modifying medication is often not reported. This review discusses the current understanding of the influence of lipid levels on cardiovascular risk in women and presents key findings on the effects of adjuvant aromatase inhibitor (AI) therapy on lipid profiles.